Serum metabolomics analysis reveals changes in signaling lipids in breast cancer patients

Biomedical Chromatography

Volumn 30, Issue 1, 2016, Pages 42-47

  Cui, Min ^a   Wang, Qiaolian ^b   Chen, Guang ^b  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

Breast cancer; Ceramide; Lysophosphatidylethanolamine; Metabolomics; Serum

Indexed keywords

BODY FLUIDS; CERAMIDES; DISEASES; FATTY ACIDS; MASS SPECTROMETRY; METABOLISM; PHOSPHOLIPIDS; PHYSIOLOGY;

BREAST CANCER; CANCER PATIENTS; INVASIVE DUCTAL CARCINOMATA; LYSOPHOSPHATIDYLETHANOLAMINE; METABOLIC PROFILING; METABOLOMIC ANALYSIS; METABOLOMICS; RISK FACTORS; SERUM; SIGNALING LIPIDS;

METABOLITES;

ACYLCARNITINE; AMINO ACID DERIVATIVE; ASPARTYLPHENYLALANINE; CERAMIDE; DIACYLGLYCEROL; GLUTACONYLCARNITINE; LIPID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE; SPHINGOMYELIN; TRYPTOPHYLLEUCINE; TYROSYLASPARTIC ACID; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID OXIDATION; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; PHOSPHOLIPID METABOLISM; PILOT STUDY; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SPHINGOLIPID METABOLISM; TIME OF FLIGHT MASS SPECTROMETRY; BLOOD; BREAST TUMOR; DISEASE COURSE; EVALUATION STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE PROGRESSION; FEMALE; HUMANS; LIPIDS; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED; PILOT PROJECTS;

EID: 84952638835     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3556     Document Type: Article

References (27)

1. Abdelsalam KE, Hassan IK and Sadig IA. The role of developing breast cancer in alteration of serum lipid profile. Journal of Research in Medical Science 2012; 17: 562-565.
2. American Cancer Society. Global Cancer Facts & Figures, 3rd edn. American Cancer Society: Atlanta; 2015.
3. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA and Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Research 2010; 70: 8309-8318.
4. Baek HM, Chen JH, Nie K, Yu HJ, Bahri S, Mehta RS, Nalcioqlu O and Su MY. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 2009; 251: 653-662.
5. Bathen TF, Jensen LR, Sitter B, Fjösne HE, Halgunset J, Axelson DE, Gribbestad IS and Lundgren S. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade and hormone status. Breast Cancer Research and Treatment 2007; 104: 181-189.
6. Chen J, Zhao X, Fritsche J, Yin P, Schmitt-Kopplin P, Wang W, Lu X, Häring HU, Schleicher ED, Lehmann R, Xu G. Practical approach for the identification and isomer elucidation of biomarkers detected in a metabonomic study for the discovery of individuals at risk for diabetes by integrating the chromatographic and mass spectrometric information. Analytical Chemistry 2008; 80: 1280-1289.
7. Choi JW and Chun J. Lysophospholipids and their receptors in the central nervous system. Biochimica et Biophysica Acta 2013; 1831: 20-32.
8. Gu H, Pan Z, Xi B, Asiago V, Musselman B and Raftery D. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer. Analytica Chimica Acta 2011; 686: 57-63.
9. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
10. Hannun YA and Obeid LM. The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. Journal of Biological Chemistry 2002; 277: 25847-25850.
11. Laisupasin P, Thompat W, Sukarayodhin S, Sornprom A and Sudjaroen Y. Comparison of serum lipid profiles between normal controls and breast cancer patients. Journal of Laboratory Physicians 2013; 5: 38-41.
12. Mahadevan S, Shah SL, Marrie TJ and Slupsky CM. Analysis of metabolomic data using support vector machines. Analytical Chemistry 2008; 80: 7562-7570.
13. Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, Godwin AK, Newman R and Mills G. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods in Enzymology 2007; 433: 1-25.
14. Nicholson JK and Wilson ID. Understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nature Reviews Drug Discovery 2003; 2: 668-676.
15. Ogretmen B and Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nature Reviews Cancer 2004; 4: 604-616.
16. Park KS, Lee HY, Lee SY, Kim MK, Kim SD, Kim JM, Yun J, Im DS and Bae YS. Lysophosphatidylethanolamine stimulates chemotactic migration and cellular invasion in SK-OV3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor. FEBS Letters 2007; 581: 4411-4416.
17. Park SJ, Lee KP, Kang S, Chung HY, Bae YS, Okajima F and Im DS. Lysophosphatidylethanolamine utilizes LPA1 and CD97 in MDA-MB-231 breast cancer cells. Cellular Signalling 2013; 25: 2147-2154.
18. Park SJ, Lee KP and Im DS. Action and signaling of lysophosphatidylethanolamine in MDA-MB-231 breast cancer cells. Biomolecules and Therapeutics 2014; 22: 129-135.
19. Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, Salas A and Ogretmen B. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncology 2010; 6: 1603-1624.
20. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T and Wishart DS. The human serum metabolome. PLoS One 2011; 6: e16957.
21. Qiu Y, Zhou B, Su M, Baxter S, Zheng X, Zhao X, Yen Y and Jia W. Mass spectrometry-based quantitative metabolomics revealed a distinct lipid profile in breast cancer patients. International Journal of Molecular Sciences 2013; 14: 8047-8061.
22. Saddoughi SA and Ogretmen B. Diverse functions of ceramide in cancer cell death and proliferation. Advances in Cancer Research 2013; 117: 37-58.
23. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE and Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR in Biomedicine 2006; 19: 30-40.
24. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C and Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-914.
25. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB and Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nature Medicine 2011; 17: 448-453.
26. Worley B and Powers R. Multivariate Analysis in Metabolomics. Current Metabolomics 2013; 1: 92-107.
27. Xu Y, Fang XJ, Casey G and Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochemical Journal 1995; 309: 933-1040.